MX2019005742A - Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina. - Google Patents

Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina.

Info

Publication number
MX2019005742A
MX2019005742A MX2019005742A MX2019005742A MX2019005742A MX 2019005742 A MX2019005742 A MX 2019005742A MX 2019005742 A MX2019005742 A MX 2019005742A MX 2019005742 A MX2019005742 A MX 2019005742A MX 2019005742 A MX2019005742 A MX 2019005742A
Authority
MX
Mexico
Prior art keywords
formula
albumin
compound
pharmaceutically acceptable
binding psma
Prior art date
Application number
MX2019005742A
Other languages
English (en)
Spanish (es)
Inventor
Berkman Clifford
Choy Cindy
Original Assignee
Cancer Targeted Tech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Targeted Tech Llc filed Critical Cancer Targeted Tech Llc
Publication of MX2019005742A publication Critical patent/MX2019005742A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/08—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with two six-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2019005742A 2016-11-23 2017-11-24 Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina. MX2019005742A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662425810P 2016-11-23 2016-11-23
PCT/US2017/063182 WO2018098390A1 (en) 2016-11-23 2017-11-24 Albumin-binding psma inhibitors

Publications (1)

Publication Number Publication Date
MX2019005742A true MX2019005742A (es) 2019-09-13

Family

ID=60812130

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005742A MX2019005742A (es) 2016-11-23 2017-11-24 Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina.

Country Status (8)

Country Link
US (1) US11147889B2 (enExample)
EP (1) EP3544960A1 (enExample)
JP (1) JP7167021B2 (enExample)
CN (1) CN109982998A (enExample)
BR (1) BR112019010206A2 (enExample)
CA (1) CA3043619A1 (enExample)
MX (1) MX2019005742A (enExample)
WO (1) WO2018098390A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7282792B2 (ja) * 2017-10-22 2023-05-29 プロビンシャル・ヘルス・サービシーズ・オーソリティ 前立腺特異的膜抗原発現癌の診断または治療のための新規放射性金属結合化合物
US20210276971A1 (en) * 2018-06-20 2021-09-09 The Research Foundation For The State University Of New York Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same
JP2022507477A (ja) * 2018-11-14 2022-01-18 ノリア・セラピューティクス・インコーポレイテッド チオアミド含有構成物
WO2020108753A1 (en) * 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
WO2020210909A1 (en) 2019-04-17 2020-10-22 Provincial Health Services Authority Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer
CA3144094A1 (en) 2019-06-21 2020-12-24 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
CN115210240A (zh) 2020-03-04 2022-10-18 日本医事物理股份有限公司 化合物及放射性标记化合物
CA3178858A1 (en) * 2020-05-06 2021-11-11 Cornell University Copper-containing theragnostic compounds and methods of use
US20240131206A1 (en) * 2020-12-04 2024-04-25 The Regents Of The University Of California Peptide receptor radionuclide therapy
US20240018110A1 (en) * 2020-12-16 2024-01-18 The University Of British Columbia Radiolabeled compounds targeting the prostate-specific membrane antigen
CN114685599A (zh) * 2020-12-30 2022-07-01 南京江原安迪科正电子研究发展有限公司 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途
EP4303213A4 (en) * 2021-03-04 2024-09-18 Nihon Medi-Physics Co., Ltd. Compound and radioactive labeling compound
US20250186627A1 (en) * 2022-03-04 2025-06-12 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
WO2024126687A1 (en) * 2022-12-16 2024-06-20 Silence Therapeutics Gmbh Nucleic acids conjugated to an albumin binding moiety
WO2024169037A1 (zh) * 2023-02-16 2024-08-22 无锡诺宇医药科技有限公司 Psma靶向放射性药物及其合成和应用
CN116217505B (zh) * 2023-03-17 2024-10-01 南京医科大学 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0621973D0 (en) * 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
EP3222617B1 (en) 2009-03-19 2022-07-06 The Johns Hopkins University Psma-targeting compounds and uses thereof
EP2739316B1 (en) 2011-08-05 2019-04-10 Molecular Insight Pharmaceuticals, Inc. Radiolabeled prostate specific membrane antigen inhibitors
US10011632B2 (en) * 2011-08-22 2018-07-03 Siemens Medical Solutions Usa, Inc. PSMA imaging agents
CN106061981A (zh) * 2013-11-06 2016-10-26 索尔斯蒂斯生物有限公司 具有二硫化物基团的多核苷酸构建体
JP6464166B2 (ja) * 2013-11-14 2019-02-06 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 陽電子放出断層撮影用の化合物
PL3183236T3 (pl) * 2014-08-24 2022-07-18 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften Sposób wytwarzania 18f-znakowanych aktywnych estrów i ich zastosowanie na przykładzie wytwarzania znacznika pet specyficznego dla psma
PL3356385T3 (pl) 2015-09-30 2021-06-28 Deutsches Krebsforschungszentrum Tagowane 18F inhibitory antygenu błonowego specyficznego dla gruczołu krokowego (PSMA) i ich zastosowanie jako środków do obrazowania w nowotworze gruczołu krokowego
SI3925952T1 (sl) * 2016-03-22 2024-03-29 The Johns Hopkins University Za prostato specifična, na membranski antigen usmerjena visoko afinitetna sredstva za endoradioterapijo raka prostate
US10179117B2 (en) * 2016-06-23 2019-01-15 Cornell University Double targeted constructs to affect tumor kill
DE102016122273B4 (de) 2016-11-18 2018-06-21 Abx Advanced Biochemical Compounds Gmbh Präkursoren für die Radiofluorierung

Also Published As

Publication number Publication date
JP2019535754A (ja) 2019-12-12
US11147889B2 (en) 2021-10-19
WO2018098390A1 (en) 2018-05-31
EP3544960A1 (en) 2019-10-02
JP7167021B2 (ja) 2022-11-08
CN109982998A (zh) 2019-07-05
BR112019010206A2 (pt) 2019-09-03
US20200061218A1 (en) 2020-02-27
CA3043619A1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
MX2019005742A (es) Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina.
CY1120480T1 (el) Ενωσεις πυραζολοπυριμιδινης
CY1125021T1 (el) Κιναζολινες ως αναστολεις διαυλων ιοντων καλιου
MX2018008168A (es) Inhibidores de antigenos de membrana especificos de la prostata (psma) basados en la urea para imaginologia y terapia.
MX2023004309A (es) Inhibidores de quinasa alk2 que contienen imidazol.
PH12018502227A1 (en) Macrocyclic mcl1 inhibitors for treating cancer
TN2019000263A1 (en) Macrocyclic compounds as ros1 kinase inhibitors
MX352672B (es) Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
WO2011116299A3 (en) Myeloid derived suppressor cell inhibiting agents
BR112012029994A2 (pt) composto heterocíclicos como inibidores de janus quinase
PH12015500360A1 (en) Pyrazolopyrimidine compound
PH12021552482A1 (en) Compounds targeting prmt5
EP3533473A3 (en) Compounds for positron emission tomography
GEP20237479B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EA201290237A1 (ru) Киназные ингибиторы
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
MX2012013206A (es) Inhibidores de quinasa biciclica fusionada.
MX2012001420A (es) Derivados de pirrolo[1,2-b]piridazina como inhibidores de cinasa janus.
EA201170617A1 (ru) Пиразолиламинопиридины в качестве ингибиторов fak
NI200900183A (es) Compuestos de pirido [2,3-d] pirimidina - 7 - ona como inhibidores de pi3k - alfa para el tratamiento del cáncer.
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
TW201613938A (en) Selective inhibitors for protein kinases, a pharmaceutical composition and an use thereof
MX2016002795A (es) Compuestos de triazolona y usos de los mismos.